Active Trader

Top Analyst Upgrades and Downgrades: Alibaba, BHP Billiton, Cintas, Monsanto, Schlumberger, Shopify, Hess, Western Digital and More

Stocks were indicated to open marginally lower on Tuesday, with no real pull from major news one way or the other. The bull market is now well over eight years ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Carbonite, Coach, Credit Suisse, DaVita, Intuit, Pandora, ONEOK, Regeneron and More

Stocks may have listed sideways for much of last week, but major indexes were indicated to open higher on Monday. The bull market is now well over eight years old, ...
Read Full Story »

Top Analyst Upgrades and Downgrades: AK Steel, Altice USA, Biogen, Caterpillar, Gilead, Oracle and Many More

Stocks have recently hit all-time highs again, but the stock indexes seem to have gone sideways in recent days and they were looking for direction on a slow news Friday. ...
Read Full Story »

Why Merrill Lynch Is Oracle’s Biggest Bull

Oracle Corp. (NYSE: ORCL) reported its fiscal fourth-quarter financial results after the markets closed and shares hit a new all-time high. Most analysts chased the stock after reading the report, ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Abercrombie, Aqua Metals, CarMax, Oracle, Southwest Air, Valero, Walmart and More

Stocks may have hit all-time highs again, but the market has taken a bit of a pause and is looking for direction. The drop in oil prices has soured some ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Abbott Labs, AMD, Chesapeake, Intel, PayPal, Target, Weatherford, Whiting Petroleum and Many More

Stocks hit all-time highs yet again this week, but the markets were directionless on Wednesday morning, with the S&P 500 down one point and the Dow up 11 points. The ...
Read Full Story »

Neos Therapeutics Slides Despite FDA Approval

Neos Therapeutics Inc. (NASDAQ: NEOS) saw its shares dip on Tuesday after the firm reported that it received approval from the U.S. Food and Drug Administration (FDA) for its treatment ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Amex, ADP, Goodyear, McDonald’s, National Oilwell Varco, NVIDIA, Vivint Solar and Many More

Stocks hit all-time highs yet again on Monday and the Dow has now gone above the 24/7 Wall St. 2017 price target issued at the start of this year. The ...
Read Full Story »

Rigel Pharma Rises Following FDA Approval

Shares of Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) saw a handy uptick on Monday after the U.S. Food and Drug Administration (FDA) approved its New Drug Application (NDA) for the use ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Amazon, Biogen, Costco, Kroger, Travelers, Wayfair and Many More

Stocks were indicated to open higher on Monday, with the Dow closing on our original 2017 price target. The bull market is now over eight years old. Every instance of ...
Read Full Story »

Clovis Oncology Surges on Clutch Late-Stage Ovarian Cancer Trial

Clovis Oncology Inc. (NASDAQ: CLVS) saw its shares make a massive gain early on Monday after the company announced top-line data from its confirmatory Phase 3 Ariel3 trial of rucaparib ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Alphabet, Enterprise Products, GrubHub, Mattel, Ryanair, Splunk and Many More

Stocks were indicated to open lower on Thursday after the markets hit new highs again on Wednesday, a day after the Federal Reserve hiked rates and announced a sooner than ...
Read Full Story »

Aldeyra Stumbles Over Mid-Stage Clinical Results

Aldeyra Therapeutics Inc. (NASDAQ: ALDX) saw its shares slide on Wednesday after the company gave an update from its mid-stage trial of topical ocular ADX-102 in patients with allergic conjunctivitis. ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Anadarko, Callaway Golf, Infinera, ONEOK, Starbucks and Many More

Stocks were indicated to open higher on Wednesday, even after the Dow hit new all-time highs on Tuesday. The S&P is expected to open within a couple points of its ...
Read Full Story »

How Omeros Won Big on This FDA Approval

Omeros Corp. (NASDAQ: OMER) saw its shares make a handy gain on Tuesday after the company announced that the U.S. Food and Drug Administration (FDA) granted a Breakthrough Therapy designation ...
Read Full Story »